- Home
- FITBI vs ZLAB Comparison
FITBI vs ZLAB Comparison
Compare FITBI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FITBI
- ZLAB
- Stock Information
- Founded
- FITBI N/A
- ZLAB 2013
- Country
- FITBI United States
- ZLAB China
- Employees
- FITBI 18616
- ZLAB N/A
- Industry
- FITBI Major Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- FITBI Finance
- ZLAB Health Care
- Exchange
- FITBI Nasdaq
- ZLAB Nasdaq
- Market Cap
- FITBI N/A
- ZLAB 3.5B
- IPO Year
- FITBI N/A
- ZLAB 2017
- Fundamental
- Price
- FITBI $25.43
- ZLAB $29.24
- Analyst Decision
- FITBI
- ZLAB Buy
- Analyst Count
- FITBI 0
- ZLAB 4
- Target Price
- FITBI N/A
- ZLAB $47.37
- AVG Volume (30 Days)
- FITBI N/A
- ZLAB 1.2M
- Earning Date
- FITBI N/A
- ZLAB 05-08-2025
- Dividend Yield
- FITBI N/A
- ZLAB N/A
- EPS Growth
- FITBI N/A
- ZLAB N/A
- EPS
- FITBI N/A
- ZLAB N/A
- Revenue
- FITBI N/A
- ZLAB $418,326,000.00
- Revenue This Year
- FITBI N/A
- ZLAB $44.43
- Revenue Next Year
- FITBI N/A
- ZLAB $48.68
- P/E Ratio
- FITBI N/A
- ZLAB N/A
- Revenue Growth
- FITBI N/A
- ZLAB 43.72
- 52 Week Low
- FITBI N/A
- ZLAB $15.65
- 52 Week High
- FITBI N/A
- ZLAB $39.77
- Technical
- Relative Strength Index (RSI)
- FITBI 47.76
- ZLAB 42.71
- Support Level
- FITBI $25.25
- ZLAB $27.61
- Resistance Level
- FITBI $25.53
- ZLAB $32.02
- Average True Range (ATR)
- FITBI 0.18
- ZLAB 1.23
- MACD
- FITBI 0.00
- ZLAB -0.18
- Stochastic Oscillator
- FITBI 40.63
- ZLAB 23.41
About FITBI Fifth Third Bancorp
Fifth Third Bancorp is a diversified financial-services company headquartered in Cincinnati. The company has over $210 billion in assets and operates numerous full-service banking branches and ATMs throughout Ohio, Kentucky, Indiana, Michigan, Illinois, Florida, Tennessee, West Virginia, Georgia, and North Carolina.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.